Rexahn Pharmaceuticals, Inc. (NYSEMKT:RNN) received a $20.00 price objective from research analysts at HC Wainwright in a research note issued to investors on Monday. The firm presently has a “buy” rating on the stock.

Several other equities research analysts also recently commented on RNN. FBR & Co set a $14.00 target price on shares of Rexahn Pharmaceuticals and gave the stock a “buy” rating in a research report on Friday, May 26th. Rodman & Renshaw reiterated a “buy” rating and set a $19.50 target price on shares of Rexahn Pharmaceuticals in a research report on Friday, June 9th. Zacks Investment Research downgraded shares of Rexahn Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Tuesday, July 18th. Finally, Ifs Securities restated an “outperform” rating on shares of Rexahn Pharmaceuticals in a report on Monday, August 7th. One investment analyst has rated the stock with a sell rating and four have assigned a buy rating to the company. The company presently has a consensus rating of “Buy” and an average price target of $17.83.

Shares of Rexahn Pharmaceuticals (RNN) traded up 3.45% during mid-day trading on Monday, reaching $2.70. 478,910 shares of the company were exchanged. Rexahn Pharmaceuticals has a 12 month low of $0.38 and a 12 month high of $7.10. The firm has a 50-day moving average price of $2.11 and a 200 day moving average price of $1.95. The stock’s market capitalization is $76.84 million.

ILLEGAL ACTIVITY WARNING: “Rexahn Pharmaceuticals, Inc. (RNN) Given a $20.00 Price Target by HC Wainwright Analysts” was posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this article on another domain, it was illegally copied and republished in violation of U.S. & international copyright laws. The legal version of this article can be accessed at

An institutional investor recently raised its position in Rexahn Pharmaceuticals stock. Renaissance Technologies LLC grew its position in shares of Rexahn Pharmaceuticals, Inc. (NYSEMKT:RNN) by 17.6% in the 1st quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 5,758,391 shares of the company’s stock after purchasing an additional 862,000 shares during the quarter. Renaissance Technologies LLC owned about 22.65% of Rexahn Pharmaceuticals worth $2,937,000 as of its most recent SEC filing.

Rexahn Pharmaceuticals Company Profile

Rexahn Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company engaged in the discovery, development and commercialization of treatments for cancer. The Company’s clinical-stage drug candidates in active development include Archexin, RX-3117 and Supinoxin (RX-5902). Archexin is a potent inhibitor of the protein kinase Akt-1, which focuses on cancer cell proliferation, survival, angiogenesis, metastasis and drug resistance.

Receive News & Stock Ratings for Rexahn Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rexahn Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.